Quality of life and functional outcomes with tapentadol prolonged release in chronic musculoskeletal pain: <i>post hoc</i> analysis

  1. Ferri, Cesar Margarit 1
  2. Natoli, Silvia 5
  3. Sanz-Ayan, Paz 2
  4. Magni, Alberto 4
  5. Guerrero, Carlos 7
  6. Lara-Solares, Argelia 6
  7. Liedgens, Hiltrud 3
  8. Thömmes, Guido 8
  9. Karra, Ravi 9
  10. Sanz Ayán, María Paz 10
  1. 1 Hospital General Universitario de Alicante, Alicante, 03010, Spain
  2. 2 Hospital Universitario 12 de Octubre; Department of Rehabilitation, Hospital Universitario 12 de Octubre, Madrid, 28041, Spain
  3. 3 Global Market Access, Grünenthal GmbH, Aachen, 52099, Germany
  4. 4 Italian College of General Practitioners & Primary Care, Florence, 50141, Italy
  5. 5 University of Rome Tor Vergata, Department of Clinical Science & Translational Medicine & Unit of Pain Therapy, Polyclinic of Tor Vergata, Rome, 00133, Italy
  6. 6 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, 14080, Mexico
  7. 7 Hospital Universitario Fundación Santa Fe, Bogotá 110121, Universidad de los Andes, Colombia
  8. 8 R&D – Development – Data Sciences, Grünenthal GmbH, Aachen, 52099, Germany
  9. 9 Global Medical Affairs, Grünenthal GmbH, Aachen, 52099, Germany
  10. 10 Universidad Complutense de Madrid
    info

    Universidad Complutense de Madrid

    Madrid, España

    ROR 02p0gd045

Mostrar afiliaciones +
Revista:
Pain Management

ISSN: 1758-1869,  1758-1877

Año de publicación: 2021

Volumen: 11

Número: 2

Páginas: 173-187

Tipo: Artículo

DOI: 10.2217/PMT-2020-0084 GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Pain Management

Resumen

To investigate quality of life (QOL) and functionality changes in chronic pain during tapentadol prolonged release (PR) treatment. Patients & methods: Post hoc analysis of data from three Phase III trials in patients with osteoarthritis knee pain or low back pain. QOL and functionality changes were assessed by SF-36 scores. Results: All SF-36 subdomain scores improved progressively to week 3 of tapentadol titration and were sustained during 12-week maintenance treatment. Improvements in SF-36 scores were similar between tapentadol dose groups (e.g., 200 to <300 mg vs ≥500 mg), with no greater effect from higher doses. QOL and functionality improvements were consistently greater with tapentadol PR than oxycodone controlled release. Conclusion: Tapentadol PR provides consistent, clinically relevant improvements in QOL and functionality in chronic pain.

€ Ver financiación

Información de financiación

Financiadores

  • Grünenthal GmbH

Referencias bibliográficas

  • 10.1016/S0140-6736(18)32335-3
  • 10.1097/j.pain.0000000000001311
  • 10.36076/ppj.2009/12/35
  • 10.1007/s00586-017-5432-9
  • 10.1590/S0034-8910.2015049005874
  • 10.1007/s11916-019-0757-1
  • Margarit C. The impact of pain; results of a survey in big 5 EU countries. (2011). https://www.sip-platform.eu/resources/details/sip-2011-plenary-session-3-may-the-impact-of-pain
  • 10.1111/ner.12018
  • 10.1007/s00296-019-04273-0
  • 10.1002/acr.22890
  • 10.1002/ejp.1409
  • 10.1002/art.23176
  • WHO Scientific Group, (2003), World Health Organ. Tech. Rep. Ser., pp. 919
  • 10.1002/art.24021
  • Woolf AD, (2003), J. Rheumatol. Suppl., 67, pp. 6
  • 10.1002/ejp.1090
  • 10.1186/1471-2474-15-213
  • 10.1136/bmjopen-2015-010364
  • 10.1016/S0140-6736(18)32279-7
  • 10.1016/j.bja.2019.03.023
  • 10.1097/BRS.0b013e3181e70488
  • 10.1007/s00586-004-0731-3
  • 10.1016/S0140-6736(18)30480-X
  • 10.1001/jama.290.18.2443
  • 10.1080/13814780903051866
  • 10.1016/j.jphys.2019.05.010
  • World Health Organization. Cancer pain relief, second edition. http://apps.who.int/iris/bitstream/10665/37896/1/9241544821.pdf
  • 10.36076/ppj.2017.s92
  • Schug SA, (2018), Medicine Today, 19, pp. 2
  • 10.1185/03007995.2014.952717
  • 10.1007/s40122-017-0068-3
  • 10.1185/03007995.2011.614934
  • 10.1016/j.ejpain.2010.06.017
  • 10.1016/j.ejpain.2010.05.005
  • 10.1124/jpet.110.175042
  • 10.1177/2049463716657363
  • 10.2165/11533440-000000000-00000
  • 10.1185/03007995.2010.537589
  • 10.1111/papr.12308
  • 10.36076/ppj.2014/17/329
  • 10.2147/JPR.S207010
  • 10.2147/JPR.S190176
  • Palexia prolonged release tablets. Summary of product characteristics. https://www.medicines.org.uk/emc/product/5158/smpc
  • Nucynta extended-release tablets PiD. https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/200533s018s019lbl.pdf
  • 10.1016/j.jpain.2014.01.489
  • 10.2147/JPR.S105892
  • 10.1016/S0885-3924(02)00411-6
  • 10.1177/2040622315627801
  • 10.2217/pmt.13.46
  • 10.5694/mja16.00133
  • 10.1097/00005650-199206000-00002
  • 10.2147/JPR.S190158
  • 10.5055/jom.2016.0349
  • 10.1007/s12325-010-0036-3
  • 10.1080/03007995.2017.1335188
  • Noble M, (2010), Cochrane Database Syst. Rev., 2010, pp. Cd006605
  • 10.1517/14656566.2010.497720
  • 10.1097/j.pain.0000000000001433
  • 10.36076/ppj.2013/16/27
  • 10.1016/j.clinthera.2014.07.005
  • 10.1185/030079906X132488
  • 10.3111/13696998.2011.642090
  • 10.1185/030079906X89874
  • 10.2165/00019053-200927020-00002
  • 10.1097/j.pain.0000000000001401
  • 10.2147/JPR.S160513
  • 10.1016/j.msksp.2016.12.006
  • 10.1002/acr.22392
  • 10.1111/papr.12361
  • 10.36076/ppj.2013/16/E237
  • 10.1016/j.clinthera.2015.08.014
  • 10.1007/s12325-011-0018-0
  • 10.5055/jom.2013.0147
  • 10.1111/j.1533-2500.2010.00397.x